Investing.com - Ascendis Pharma AS (NASDAQ: ASND) reported first quarter EPS of €-2.30, €0.82 worse than the analyst estimate of €-1.48. Revenue for the quarter came in at €95.89M versus the consensus estimate of €79.49M.
Ascendis Pharma AS's stock price closed at €141.10. It is up 0.95% in the last 3 months and up 54.11% in the last 12 months.
Ascendis Pharma AS saw 3 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Ascendis Pharma AS's stock price’s past reactions to earnings here.
According to InvestingPro, Ascendis Pharma AS's Financial Health score is "fair performance".
Check out Ascendis Pharma AS's recent earnings performance, and Ascendis Pharma AS's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar